Ruxolitinib for myelofibrosis: Indication of considerable added benefit

ScienceDaily
Aug 19, 2014, 12:59 pm32 pts
In comparison with 'best supportive care', there is an indication that the new drug is better at relieving symptoms, and a hint of longer survival. Myelofibrosis is a rare disease of the bone marrow, in which the bone marrow is replaced by connective tissue. As a consequence of this so-called fibrosis, the bone…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on EcoTopical

UK Accused of ‘Helping Russia’ as Refined Oil Imports From ‘Laundering’ Countries Remain at Record High 120

Mechanism of grafting Prunus sp. to control crown gall disease by regulating the rhizosphere environment 101

Biden-Harris Administration Announces Final Transmission Permitting Rule & Latest Investments to Accelerate the Buildout of a Resilient, Reliable, Modernized Electric Grid 101

Team reports on relationship between contents of diosgenin and brassinosteroids in Dioscorea zingiberensis 100

U.S. DOE Reduces Regulatory Hurdles For Solar, Energy Storage, & Transmission Projects 96

African Brazilian communities fight a rain of pesticides & the company behind it 91

‘Pathetic, Really, and Dangerous’: Al Gore Reflects on Fraudulent Fossil Fuel Claims, Climate Voters and Clean Energy 87

$362 Million Loan to CelLink to Support Domestic Manufacturing of Key Electric Vehicle Supply Chain Components 84

About EcoTopical

Welcome to EcoTopical Your daily eco-friendly green news aggregator.

Leaf through planet Earths environmental headlines in one convenient place. Read, share and discover the latest on ecology, science and green living from the web's most popular sites.